ALISO VIEJO, Calif., May 9, 2011 /PRNewswire/ — Avanir
Pharmaceuticals, Inc. (NASDAQ:
AVNR) today announced the appointment of Elona Kogan, Esq. to
the position of vice president of legal affairs.
“At this time of growth and transition to a commercial stage
biopharmaceutical company, Elona’s legal, regulatory and business
expertise will be a valuable asset to our organization,” said Keith
A. Katkin, president and CEO of Avanir. “The executive team and I
are pleased to have Elona’s extensive experience and expert counsel
as we move ahead with our exciting new endeavors.”
Ms. Kogan has over 17 years of experience covering areas of
commercial and regulatory compliance, patient assistance programs,
privacy issues, contracting, litigation and corporate governance.
Most recently Ms. Kogan was associate general counsel and privacy
officer at King Pharmaceuticals, where she was the primary legal
liaison for corporate strategic and tactical commercial
initiatives. Previously, Ms. Kogan was counsel for U.S. Medicines
at Bristol-Myers Squibb. Prior roles included positions at Bergen
Brunswig Corporation, and Epstein, Becker & Green. Ms. Kogan
earned her J.D. degree from Southwestern University and her B.A.
degree in Economics from Columbia University.
About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company
focused on bringing innovative medicines to patients with central
nervous system disorders of high unmet medical need. As part of our
commitment, we have extensively invested in our pipeline and are
dedicated to advancing medicines that can substantially improve the
lives of patients and their loved ones. For more information about
Avanir, please visit www.avanir.com.
AVANIR™ is a trademark owned by Avanir Pharmaceuticals,